影响抗抗体治疗淋巴细胞亚群CD4和刺激肿瘤坏死因子α生产

文摘

T淋巴细胞可能在寻找女士发挥核心作用比目前更多的有针对性的免疫抑制导致了最近的小说疗法的临床试验。我们研究了29名在一个双盲安慰剂对照试验的嵌合单克隆抗体anti-CD4 cM-T412(年会、莱顿、荷兰)在18个月。道达尔和微分的白细胞计数;T、B和自然杀伤淋巴细胞;CD4 +和CD8 + T细胞;CD4 +、CD4 -幼稚细胞;CD4 +、CD4 -记忆细胞;白介素2受体,主要组织相容性类II-positive T细胞;血清肿瘤坏死因子α(TNF-α);和PHA(植物凝集素)/有限合伙人(脂多糖)刺激全血TNF-α生产都在外周血检查连续试验的持续时间。 In addition, for the first two treatment cycles, the above variables were tested 1 and 7 days after treatment. The results demonstrated significant long-term reductions, lasting up to 12 months after the last treatment cycle in all CD4+ subsets studied, but with a relative preservation of CD4+ memory cells as opposed to CD4+ naive cells. CD4– subsets also showed significant reductions after treatment but returned to baseline levels within 7 days. Monocyte counts were unaffected by cM-T412. Serum TNF-α and 2– and 18-hour PHN/LPS-stimulated TNF-α levels were also unchanged in the long term, although significant increases were observed in the 2– and 18-hour PHA/LPS-stimulated TNF-α levels the day immediately after treatment. There was no significant correlation between any of the immunologic markers studied and MRI measures of disease activity.